PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Enbio turned profitable in 2024 after consecutive losses in 2022-2023, but quarterly earnings volatility and governance concerns persist.
2025 consolidated revenue was KRW 33.95 billion with operating profit of KRW 0.92 billion (2.7% margin), a lower margin than the prior year but still profitable.
Q1 2026 operating profit reached KRW 3.13 billion, the strongest recent quarter, before slowing sharply to KRW 0.17 billion in Q2.
Expansion of the NongHyup special sales channel and herbicide/fungicide exports drove H1 2026 top-line growth.
The company secured a new plant site in the Buron Industrial Complex in Wonju, Gangwon Province, to expand production capacity.
A KRW 20 billion share buyback plan and executive share purchases continue, even as a designation as an unfaithful disclosure company has drawn attention.
Founded in 1997 and listed on KOSDAQ in 2020, Enbio is a crop protection specialist that manufactures and sells fungicides, insecticides, herbicides and fertilizers.
Its core products include the eco-friendly lime-sulfur compound and the broad-spectrum insecticide Indoema, and the company has developed and registered over 100 products over the past decade.
Distribution runs through two channels: systematic sales via NongHyup Economic Federation and regional cooperatives, and self-operated retail branches nationwide; the company has recently expanded to 17 special NongHyup sales branches.
As of April 2026, Enbio maintained a portfolio of 173 crop protection products, with the roughly KRW 1.2 trillion NongHyup systematic supply market serving as its core distribution backbone.
Over the past three to four years the company restructured its own retail branch client base toward higher-quality accounts to improve sales efficiency.
It is also pursuing new drug development, including filing what it describes as the world's first virus treatment registration, alongside joint development of new substances for medium-term growth.
Domestic competitors include Kyung Nong, Sungbo Chemicals, and Chobi, which are frequently cited together in seasonal demand narratives such as monsoon-related crop protection demand.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩8.5B | -₩200M | −2.0% |
| 2025Q3 | ₩3.9B | -₩1.3B | −34.1% |
| 2025Q4 | ₩7.7B | -₩700M | −9.5% |
| 2026Q1 | ₩14.1B | ₩3.1B | 22.1% |
| 2026Q2 | ₩10.4B | ₩200M | 1.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩34.2B | -₩4.8B | -₩3.4B | −14.0% | −7.4% | 87.9% |
| 2023 | ₩34B | -₩3.4B | -₩6.3B | −9.9% | −15.5% | 62.8% |
| 2024 | ₩35.7B | ₩1.4B | ₩600M | 3.9% | 1.6% | 63.8% |
| 2025 | ₩34B | ₩900M | ₩1B | 2.7% | 2.4% | 63.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual results show two consecutive loss-making years: revenue of KRW 34.24 billion with an operating loss of KRW 4.78 billion (-14.0% margin) in 2022, and revenue of KRW 34.02 billion with an operating loss of KRW 3.35 billion (-9.9%) in 2023.
In 2024, revenue rose to KRW 35.65 billion and operating profit turned positive at KRW 1.41 billion (3.9% margin). However, in 2025 revenue declined again to KRW 33.95 billion and operating profit fell to KRW 0.92 billion (2.7%), showing margin compression.
Net profit, however, increased to KRW 1.01 billion in 2025 from KRW 0.65 billion in 2024, suggesting non-operating factors contributed to the bottom-line improvement.
Quarterly results show pronounced volatility: Q3 2025 revenue was KRW 3.94 billion with an operating loss of KRW 1.34 billion, and Q4 2025 continued the loss trend with revenue of KRW 7.66 billion and an operating loss of KRW 0.73 billion.
In contrast, Q1 2026 revenue surged to KRW 14.14 billion with operating profit of KRW 3.13 billion and net profit of KRW 2.21 billion, the strongest of the last five quarters.
Q2 2026 revenue was KRW 10.44 billion with operating profit narrowing sharply to KRW 0.17 billion, and net profit slipped to a small loss of KRW 0.04 billion, reaffirming the seasonal pattern where operating results diverge widely by quarter.
This pattern points to a business structure concentrated around the spring farming season, with revenue and profit clustering in Q1 and early Q2 and relative weakness in the second half.
The domestic crop protection industry faces a structural mix of rising demand for labor-saving compound products—driven by farm population decline and aging—alongside limited overall demand growth due to free trade agreements and environmental concerns.
Climate change and the increase in invasive pests are boosting demand for new product development, prompting companies including Enbio to pursue eco-friendly products tailored to local conditions in new markets.
The NongHyup Economic Federation's systematic supply market, roughly KRW 1.2 trillion in size, is the industry's core distribution channel, and competition for share within this channel has a direct bearing on company results.
During seasonal demand events such as the monsoon season, major domestic crop protection companies including Enbio, Kyung Nong, Sungbo Chemicals, and Chobi tend to be cited together as beneficiaries, indicating that sector performance is sensitive to weather conditions as much as to individual competitive positioning.
On the export front, Enbio reported that its H1 2026 herbicide exports rose 567% year-on-year and fungicide exports rose 153%, indicating progress in overseas channel expansion.
Overall, the domestic crop protection market appears to have matured, with growth increasingly dependent on individual companies' execution around product diversification, overseas expansion, and channel restructuring.
The company has set a 2026 target of over KRW 12 billion in NongHyup channel sales, citing 132% year-on-year growth in Q1 NongHyup sales to KRW 3.8 billion and 71% growth for H1 overall as grounds for confidence in reaching that target.
A company representative stated that in the second half it will focus on sustaining stable sales growth in existing businesses while pursuing new product expansion and joint development of new substances to secure medium-term growth momentum.
On the production side, the company secured a roughly 8,000-pyeong new plant site in the Buron Industrial Complex in Wonju, Gangwon Province, with plans to expand production capacity more than twofold versus existing facilities along with process automation.
Shareholder return policy is also advancing: the company stated it has secured KRW 20 billion in funding and is considering a medium-term buyback of 5-10% of total shares outstanding, while an extraordinary shareholders' meeting in June 2026 approved a resolution to transfer capital reserves to retained earnings to offset accumulated deficits.
Management has also signaled commitment, with CEO Lee Myung-jae purchasing 108,383 shares on the open market over five months from October 2025 to raise his stake, and the company stated that other senior executives continued share purchases in 2026.
However, the specific timing and scale of these plans will need to be confirmed through future board resolutions and disclosures.
Enbio's net profit turned from losses in 2022-2023 to positive territory in 2024 and maintained that profitable stance through 2025, with a modest net profit also recorded over the trailing four quarters, underscoring the small-cap scale of its earnings base.
The shares tend to trade at a discount to net asset value, which may reflect a cautious market view on earnings stability. Dividend history shows no clear recent payout pattern, limiting the stock's appeal on a yield basis relative to other chemical and agrochemical peers.
That said, the company's announced buyback plan and rising executive shareholdings are notable from a shareholder-return perspective, and how these plans are executed and scaled could influence how the market assesses valuation going forward.
Given the pronounced seasonal swings in earnings, it may be more informative to weigh annual trends and quarterly patterns together rather than relying on any single quarter's results for valuation purposes.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
After posting consecutive operating losses in 2022-2023, Enbio achieved an operating profit turnaround in 2024 and sustained profitability through 2025. Q1 2026 operating profit reached KRW 3.13 billion, the strongest recent quarter.
The company attributes this to portfolio restructuring toward higher-margin products and efforts to secure new revenue sources.
Enbio operates 17 special NongHyup sales branches nationwide, and Q1 2026 NongHyup channel sales grew 132% year-on-year to KRW 3.8 billion, with H1 growth reaching 71%. The company set a 2026 NongHyup sales target of over KRW 12 billion.
Leveraging Korea's largest agricultural materials distribution network has become a core driver of top-line growth.
Enbio stated it has secured KRW 20 billion in funding and is considering a medium-term buyback of 5-10% of total shares outstanding. CEO Lee Myung-jae purchased 108,383 shares on the open market over five months from October 2025, and other senior executives continued share purchases in 2026.
A resolution to transfer capital reserves to retained earnings to offset accumulated deficits was also approved at an extraordinary shareholders' meeting in June 2026.
Operating losses recurred in the second half of 2025, with Q3 losses of KRW 1.34 billion and Q4 losses of KRW 0.73 billion. In Q2 2026, despite solid revenue of KRW 10.44 billion, operating profit was only KRW 0.17 billion and net profit registered a small loss.
Given the structure concentrated around the peak farming season, second-half earnings improvement remains uncertain.
The KOSDAQ Market Division of the Korea Exchange previously flagged Enbio for designation as an unfaithful disclosure company, citing delayed disclosures related to embezzlement and breach-of-trust allegations.
In 2022, a former in-house director faced a breach-of-trust allegation involving unauthorized leakage of test certificates, which led to a criminal complaint. These recurring disclosure and internal control issues could weigh on investor confidence.
The debt ratio declined from 87.9% in 2022 to the low-60% range in 2023-2025, but debt relative to net assets remains present. External data indicate the current ratio fell from 185.8% in 2023 to 167.6% in 2025, suggesting a modest reduction in short-term liquidity buffer.
If new plant investment and share buybacks occur concurrently, managing financial capacity could become an important variable.
The prior warning of designation as an unfaithful disclosure company, along with a history of embezzlement and breach-of-trust allegations, may raise concerns about disclosure reliability.
The company has pledged to improve its internal control system, but whether this materializes will need confirmation through future disclosures and audit outcomes. If such issues recur, rebuilding market trust could take time.
Demand for crop protection products is sensitive to weather conditions such as rainfall and pest outbreak severity. A structure where benefits concentrate in specific seasons, such as the monsoon period, can conversely amplify earnings volatility if weather patterns diverge from expectations. This is not unique to Enbio but a structural factor across the entire domestic crop protection industry.
The new Buron Industrial Complex plant is still at the site-acquisition stage, requiring further funding and permitting procedures before construction and operation. If buyback funding and new plant investment funding are required simultaneously, prioritizing capital allocation becomes important. If the timeline slips relative to plans, the capacity expansion benefit may materialize later than expected.
Check Q3 2026 earnings disclosure (including preliminary figures) to see whether the second-half seasonal weakness recurs and whether new-product/export expansion effects show through.
Check for further disclosures on the construction start timing and permitting progress for the Wonju Buron Industrial Complex plant, an indicator of whether capacity expansion plans are being concretely executed.
Confirm whether the company follows through with its previously announced board resolution and actual commencement of the share buyback (5-10% of shares outstanding, KRW 20 billion funding).
Check for disclosures on follow-up measures and internal control improvement plans related to the Korea Exchange's unfaithful disclosure company designation, an indicator of whether governance risk is easing.
Check whether annual NongHyup channel sales met the KRW 12 billion-plus target and whether full-year revenue and profit improved versus 2025.
Enbio turned profitable in 2024 after consecutive losses in 2022-2023, and posted its strongest recent quarterly operating profit in Q1 2026, reflecting gains from NongHyup channel expansion and export growth.
However, the sizable losses in Q3-Q4 2025 and the sharp margin decline in Q2 2026 reaffirm that earnings remain seasonally concentrated and volatile.
The company has announced a series of growth and shareholder-return initiatives, including a KRW 20 billion buyback plan, expanded executive shareholdings, and securing a new plant site in the Wonju Buron Industrial Complex, though the specific timing and scale of execution for these plans remain unconfirmed.
At the same time, governance-related issues—including a prior warning of designation as an unfaithful disclosure company and a history of breach-of-trust allegations—warrant continued attention.
The debt ratio has shown an improving trend, but external data suggest the current ratio has eased somewhat, making financial capacity management another point to monitor.
Ahead of any investment decision, it would be useful to comprehensively track the upcoming Q3 results, new plant progress, buyback execution, and governance-improvement disclosures.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.